NCT05658549

Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Universitas Sebelas Maret · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.

Detailed description

This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group K1 received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	N-acetyl cysteine	N-acetyl cysteine dosage 600 mg and 1200 mg

Timeline

• Start date: 2021-05-01
• Primary completion: 2021-07-30
• Completion: 2021-07-30
• First posted: 2022-12-20
• Last updated: 2022-12-20

Locations

1 site across 1 country: Indonesia